BiomX Inc., a clinical-stage company, has shared its corporate presentation detailing its ongoing efforts to address the urgent need for novel therapies to combat antibiotic resistance. The presentation highlights BiomX's innovative approach, focusing on phage therapy trials that have demonstrated statistically significant clinical efficacy in treating chronic bacterial infections. The company emphasizes the added benefits of phage therapeutics, particularly in high-need indications where no approved treatments currently exist. BiomX is at the forefront of developing phage therapy solutions, which are becoming increasingly critical due to rising antibiotic resistance. You can access the full presentation through the link below.